Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have earned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $12.67.

A number of equities research analysts have recently commented on the company. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright initiated coverage on Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target for the company. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Tuesday, January 7th. Finally, StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th.

Immunic Price Performance

NASDAQ IMUX opened at $1.05 on Friday. The company has a market capitalization of $94.58 million, a P/E ratio of -0.85 and a beta of 1.88. Immunic has a 12 month low of $0.97 and a 12 month high of $2.11. The company’s 50 day simple moving average is $1.13 and its 200 day simple moving average is $1.32.

Insider Buying and Selling

In other news, Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 3.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Immunic during the third quarter valued at about $50,000. Jane Street Group LLC lifted its position in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. Finally, State Street Corp grew its holdings in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.